![logo](/logos/300584.SZ.webp)
Nanjing Hicin Pharmaceutical Co., Ltd.
SZSE:300584.SZ
24.7 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 506.54 | 526.465 | 578.315 | 706.296 | 924.538 | 711.908 | 455.035 | 280.828 | 220.993 | 197.655 | 169.502 | 147.953 |
Cost of Revenue
| 129.961 | 130.017 | 109.01 | 171.561 | 187.155 | 98.05 | 95.288 | 91.202 | 85.105 | 79.345 | 74.061 | 69.979 |
Gross Profit
| 376.579 | 396.448 | 469.305 | 534.734 | 737.383 | 613.858 | 359.747 | 189.625 | 135.889 | 118.31 | 95.441 | 77.974 |
Gross Profit Ratio
| 0.743 | 0.753 | 0.812 | 0.757 | 0.798 | 0.862 | 0.791 | 0.675 | 0.615 | 0.599 | 0.563 | 0.527 |
Reseach & Development Expenses
| 44.568 | 18.217 | 21.697 | 31.876 | 36.098 | 37.534 | 31.35 | 23.627 | 18.227 | 15.949 | 12.511 | 0 |
General & Administrative Expenses
| 23.815 | 16.502 | 18.861 | 12.528 | 14.26 | 14.097 | 9.111 | 7.264 | 5.681 | 5.866 | 5.417 | 24.122 |
Selling & Marketing Expenses
| 241.596 | 268.706 | 342.878 | 385.432 | 531.195 | 437.956 | 218.731 | 85.857 | 50.27 | 42.476 | 30.875 | 23.156 |
SG&A
| 283.888 | 285.208 | 361.738 | 397.959 | 545.455 | 452.053 | 227.842 | 93.121 | 55.951 | 48.342 | 36.292 | 47.278 |
Other Expenses
| -4.681 | -1.325 | 305.282 | -1.16 | -0.105 | -0.548 | -1.292 | 0.649 | 2.246 | 1.154 | 1.363 | -0.187 |
Operating Expenses
| 333.138 | 351.712 | 435.202 | 462.967 | 614.653 | 513.42 | 280.753 | 134.489 | 88.435 | 76.388 | 57.603 | 48.642 |
Operating Income
| 43.441 | 30.101 | 331.3 | 62.506 | 114.266 | 96.517 | 77.583 | 52.076 | 45.47 | 40.052 | 37.396 | 30.128 |
Operating Income Ratio
| 0.086 | 0.057 | 0.573 | 0.088 | 0.124 | 0.136 | 0.17 | 0.185 | 0.206 | 0.203 | 0.221 | 0.204 |
Total Other Income Expenses Net
| -5.752 | -1.325 | -0.853 | -1.16 | -0.105 | -0.548 | -1.292 | 0.383 | 1.973 | -0.268 | 1.363 | -0.38 |
Income Before Tax
| 37.689 | 28.776 | 330.447 | 61.346 | 114.161 | 95.969 | 76.29 | 52.46 | 47.444 | 39.785 | 38.759 | 29.748 |
Income Before Tax Ratio
| 0.074 | 0.055 | 0.571 | 0.087 | 0.123 | 0.135 | 0.168 | 0.187 | 0.215 | 0.201 | 0.229 | 0.201 |
Income Tax Expense
| 1.374 | -3.348 | 45.615 | 6.82 | 17.003 | 12.746 | 10.69 | 7.223 | 7.115 | 5.571 | 5.471 | 4.156 |
Net Income
| 36.316 | 32.449 | 285.878 | 55.23 | 97.258 | 83.223 | 65.601 | 45.236 | 40.329 | 34.214 | 33.287 | 25.592 |
Net Income Ratio
| 0.072 | 0.062 | 0.494 | 0.078 | 0.105 | 0.117 | 0.144 | 0.161 | 0.182 | 0.173 | 0.196 | 0.173 |
EPS
| 0.3 | 0.27 | 2.38 | 0.46 | 0.81 | 0.69 | 0.56 | 0.5 | 0.45 | 0.38 | 0.37 | 0 |
EPS Diluted
| 0.3 | 0.27 | 2.38 | 0.46 | 0.81 | 0.69 | 0.56 | 0.5 | 0.45 | 0.38 | 0.37 | 0 |
EBITDA
| 97.001 | 92.496 | 377.013 | 102.399 | 150.865 | 118.372 | 95.589 | 68.536 | 60.684 | 53.265 | 43.166 | 27.881 |
EBITDA Ratio
| 0.191 | 0.176 | 0.652 | 0.145 | 0.163 | 0.166 | 0.21 | 0.244 | 0.275 | 0.269 | 0.255 | 0.188 |